News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase II
Soligenix (SNGX) Announces Positive Recommendation By Data Review Committee On Its Phase 2 Clinical Trial Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients 3/3/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Receipt Of Orphan Drug Designation From The U.S. FDA For Primary Peritoneal Cancer 3/3/2015
Aquinox Pharmaceuticals (AQXP) Completes Enrollment In The Phase II LEADERSHIP Trial Of AQX-1125 In Bladder Pain Syndrome/Interstitial Cystitis 3/3/2015
Biota Pharmaceuticals, Inc. (BOTA) Commences Dosing In Vapendavir SPIRITUS Phase IIb Trial 3/3/2015
DURECT Corporation (DRRX) Announces Epigenomic Regulator Program Including A New NAFLD/NASH And Acute Organ Injury Product Candidate In Development 3/3/2015
MediciNova, Inc. Release: MN-166 (Ibudilast) Effects In Opioid Dependence Selected For Presentation At The 77th Annual Meeting Of The College On Problems Of Drug Dependence In Phoenix, Arizona 3/3/2015
Amgen (AMGN) Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 3/3/2015
Prima Biomed (PRR.AX) To Prioritize Immuno-Oncology Programs Targeting Immune Checkpoint LAG-3 3/3/2015
Opko Health, Inc. (OPK) Release: Twelve Months Data Supporting Once-Weekly Dosing Of Hgh-CTP In Growth Hormone Deficient Pediatric Population To Be Presented At ENDO 2015 Conference 3/3/2015
GlycoMimetics, Inc. (GLYC) Announces Publication Of Phase 2 Data For Rivipansel In Sickle Cell Disease 3/3/2015
Vince & Associates Clinical Research Completes CymaBay Therapeutics’ Clinical Trial Of Arhalofenate In Combination With Febuxostat 3/3/2015
Melior Pharmaceuticals Initiates Phase 2 Study With MLR-1023 For Type 2 Diabetes 3/3/2015
New Jersey Startup Celimmune Aims to Give New Life to Shelved Amgen (AMGN) Drug 3/2/2015
Transition Therapeutics Inc. (TTH.TO) Announces Enrolment Completion Of ELND005 Phase 2 Clinical Study In Agitation And Aggression In Patients With Alzheimer's Disease 3/2/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Receipt Of Orphan Drug Designation From The U.S. FDA For Cancer Of The Fallopian Tube 3/2/2015
Acasti Pharma Receives Full Data For Phase II TRIFECTA Trial 3/2/2015
Aldeyra Therapeutics (ALDX) Provides Update On NS2 Clinical Program 3/2/2015
Ohr Pharmaceutical (OHRP) Announces Additional Positive Anatomic Data From The OHR-102 IMPACT Study Interim Analysis Presented At Annual Macula Society Meeting 3/2/2015
Acceleron Pharma Presents Encouraging Response Rates And Progression-Free Survival Data In Patients With Advanced Renal Cell Carcinoma At The American Society Of Clinical Oncology (ASCO) 2015 Genitourinary Cancers Symposium 3/2/2015
Alizé Pharma Launches Phase 2 Clinical Trial Of AZP-531 In Prader-Willi Syndrome 3/2/2015
BioLineRx Ltd. Announces Regulatory Submission For Phase 2b Trial For Novel AML Consolidation Treatment 3/2/2015
Opsona Therapeutics Ltd. Commences Part B Of Phase II Study Of Blocking Toll-Like Receptor 2 In Extended Criteria Donor Renal Transplant Recipients At High Risk Of Early Graft Dysfunction 3/2/2015
Clearside Biomedical Initiates Phase 2 Clinical Trial To Evaluate Reducing Treatment Visits While Improving Outcomes In Macular Edema Associated With Retinal Vein Occlusion 3/2/2015
Isis Pharmaceuticals, Inc. (ISIS) Earns $15 Million From GlaxoSmithKline (GSK) for Advancing ISIS-TTR Rx 3/2/2015
ABIVAX Recruits First Patient In A Pivotal Phase 2b/3 Clinical Trial With ABX203, A Novel Immunotherapy Against Chronic Hepatitis B 2/26/2015
Phosphate Therapeutics Announces Completion Of Subject Recruitment Into The PEACH Pivotal Phase 2 Study Of Its Novel Phosphate Binder (PT20) For The Treatment Of Hyperphosphataemia 2/26/2015
Sangamo BioSciences (SGMO) Presents New Clinical Data At CROI 2015 From Trial Of ZFP Therapeutic Designed To Provide Functional Control Of HIV 2/26/2015
Columbia Laboratories, Inc. (CBRX) To Initiate A Phase 2 Clinical Trial For COL-1077, Lidocaine Bioadhesive 10% Gel, In The Second Quarter Of 2015 2/26/2015
Progenics Pharmaceuticals, Inc. (PGNX) Presents Positive Phase 2 Data For PSMA ADC In Metastatic Castration-Resistant Prostate Cancer 2/26/2015
Aduro Biotech Collaborates With Leaders In Cancer Research On Investigator-Sponsored Phase 2 Trial Combining Aduro’s Innovative Immunotherapies With Anti-PD-1 Technology To Treat Patients With Advanced Pancreatic Cancer 2/26/2015
Afferent Corporation Clinical Data For Lead Candidate, AF-219, Demonstrate Improvements In Pain And Urinary Urgency In Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS) 2/26/2015
ISA Pharmaceuticals Announces Start Of First Phase 1/2 Clinical Trial Of Its SLP®-AMPLIVANT® Conjugates 2/26/2015
TherapeuticsMD, Inc.  (TXMD) Has "Multiple Catalysts" in 2015/16 As Products Develop, Says Cowen and Company 2/26/2015
MicuRx Pharmaceuticals Initiates U.S. Phase 2 Clinical Trial For Novel Antibiotic MRX-I 2/25/2015
Valeant (VRX) Release: PROVENGE (sipuleucel-T) Demonstrates Sustained Immune Response Two Years After Treatment In Biochemically-Recurrent Prostate Cancer 2/25/2015
Dilafor Announces Positive Results From A Multi Dosing Safety And Pharmacokinetic Clinical Study 2/25/2015
Pfizer (PFE)'s Meningitis B Vaccine Meets Safety, Tolerability Goals in Mid-Stage Study 2/25/2015
Neurotrope Announces Positive Top-Line Results From Its Phase 2a Study Of Bryostatin-1 In Alzheimer's Disease 2/24/2015
Progenics Pharmaceuticals, Inc. (PGNX) To Present Full Phase 2 Data For PSMA ADC At The 2015 American Society of Clinical Oncology GU Symposium 2/24/2015
Flexion Therapeutics (FLXN) Completes Enrollment In Pivotal Phase 2b Confirmatory Clinical Trial With Lead Compound FX006 2/24/2015
Galectin Therapeutics Announces Details Of The Design Of Its Phase 2 Program With GR-MD-02 2/24/2015
OncoGenex Pharmaceuticals Inc. (OGXI) And Sarah Cannon Research Institute Announce Completion Of Patient Enrollment In The Spruce Clinical Trial Evaluating Apatorsen In Combination With Carboplatin And Pemetrexed In Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer 2/24/2015
Teva Pharmaceutical Industries (TEVA) Announces Positive Results For TEV-48125 In Phase IIb Chronic Migraine Study Meeting Primary And Secondary Endpoints 2/24/2015
Celldex (CLDX)'s Rindopepimut Deemed a Breakthrough By the FDA 2/24/2015
Celldex (CLDX)'s Rindopepimut (Rintega) Receives FDA Breakthrough Therapy Designation For The Treatment Of Adult Patients With Egfrviii-Positive Glioblastoma 2/23/2015
Shares Surge as Novo Nordisk A/S (NVO) Shows Off Positive Trial Data for Oral Insulin 2/23/2015
ContraVir Pharmaceuticals Provides Clinical Update On FV-100 2/23/2015
Savara's AeroVanc Meets Primary Endpoint Of MRSA Reduction In Phase 2 Trial In People With Cystic Fibrosis 2/23/2015
Boehringer Ingelheim Corporation Release: New Phase 2 Data In Asthma Patients Show Tiotropium Improves Lung Function, Regardless Of Allergic Status 2/23/2015
Eiger Biopharma Announces Presentation Of Positive Data In Patients Infected With Hepatitis Delta Virus (HDV) Treated With Lonafarnib 2/23/2015
Emisphere Technologies, Inc. (EMIS) Highlights Positive Phase 2 Og217sc Data From Eligen Licensee Novo Nordisk A/S (NVO) 2/23/2015
Results from AbbVie (ABBV)'s Study Of VIEKIRA PAK (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) In Chronic Hepatitis C Patients With HIV-1 Co-Infection (TURQUOISE-I) Published Online In JAMA; Sub-Analyses To Be Presented At The Annual Conference On Retroviruses And Opportunistic Infections (CROI) 2/23/2015
NovoCure Ltd. Enrolls The First Patient In Its Phase II STELLAR Trial Of Tumor Treating Fields Together With Pemetrexed And Cisplatin Or Carboplatin For The Treatment Of Malignant Mesothelioma 2/23/2015
Addex Therapeutics (ADXN.SW) Initiates Dipraglurant Receptor Occupancy Clinical Study In Collaboration With Johns Hopkins University With Funding From The Michael J. Fox Foundation 2/23/2015
Galapagos NV (GLPG.BR) Reports That The Last Patient In Darwin 1 Has Completed 12 Weeks Of Treatment 2/23/2015
Anergis Presents Sustained Efficacy Data From Its Allert Phase 2b Trial At The AAAAI Annual Meeting 2/23/2015
TRICON: Alzheimer's Drug Saw 80% Reversal in Memory Loss, Say Anavex (AVXL) CEO 2/20/2015
Novo Nordisk A/S (NVO) Announces Positive Results For Phase 2 Trial With Oral Semaglutide In People With Type 2 Diabetes 2/20/2015
Xenon Pharmaceuticals Inc. Partner Teva Pharmaceutical Industries (TEVA) To Initiate Phase 2b Clinical Trial Of TV-45070 In Post-Herpetic Neuralgia 2/20/2015
Cerecor Inc. Bolsters Clinical Pipeline With Acquisition Of Phase 2-Ready Kappa Opioid Receptor Antagonist From Eli Lilly (LLY) 2/20/2015
Pierre Fabre Release: A phase 2/3 Clinical Data Published In The NEJM Confirms Positive Safety-Efficacy Profile For First Pediatric Treatment For Infantile Hemangioma 2/20/2015
Ocera Therapeutics, Inc. (OCRX) Announces Preliminary Topline Results From Phase 2a Investigator-Sponsored Study Of OCR-002 2/19/2015
Merrimack Pharmaceuticals Inc. (MACK) Announces Initiation Of A Phase 2 Biomarker-Selected Clinical Trial Of MM-121 In Patients With Heregulin Positive Non-Small Cell Lung Cancer 2/19/2015
Omeros Corporation (OMER)'s Phase 2 OMS721 Trial Resulting in Extended Access for Compassionate Use 2/19/2015
Northwest Biotherapeutics (NWBO)'s Phase 3 Trial Of Dcvax-L For Gbm Brain Cancer Approved To Proceed In Canada And Under Way At Two Sites 2/19/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Completion Of Enrollment In Randomized Phase 2 Colorectal Cancer Study 2/18/2015
Oncoceutics Release: Article In Cancer Research Identifies Biomarkers And Combination Therapies That Hone Path To ONC201 Clinical Success 2/18/2015
VBL Therapeutics (VBLX) Announces Removal Of FDA Partial Clinical Hold On VB-111 2/17/2015
MediciNova, Inc. Provides Update On Clinical Trial Of MN-166 (Ibudilast) In ALS 2/17/2015
BioTie Therapies Corp.: BTT1023 Receives Positive Opinion For Orphan Drug Designation From COMP 2/17/2015
Celsus Therapeutics (CLTX) Announces That The Phase II Trial Of MRX-6 Cream 2% In Pediatric Atopic Dermatitis Did Not Reach Primary Endpoint 2/17/2015
VBL Therapeutics (VBLX) Reports Topline Results From Phase 2 Studies Of VB-201 In Psoriasis And Ulcerative Colitis 2/17/2015
Generex Biotechnology Corporation (GNBT) Provides Update On Antigen Express Phase 2 AE37 Breast Cancer Vaccine Trial 2/17/2015
Helix Biopharma (TSX:HBP) Initiates Enrollment for Eleventh Cohort in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47 2/17/2015
VistaGen Therapeutics, Inc. And NIH Sign Agreement For NIH-Sponsored Phase 2 Study Of Orally-Active AV-101 In Major Depressive Disorder 2/17/2015
Pharmacyclics, Inc. (PCYC) Release: IMBRUVICA (ibrutinib) Treatment Shows Efficacy And Tolerability In Heavily Treated Chronic Lymphocytic Leukemia Patients Following Allogeneic Stem Cell Transplant 2/17/2015
Cytori Therapeutics, Inc. (CYTX) Begins Enrollment In ACT-OA: US Phase II Trial For Knee Osteoarthritis 2/17/2015
Cell Cure Neurosciences Ltd. Provides Update On Its Product Development And Partnering Activities 2/17/2015
Lightlake Therapeutics Inc. (LLTP) Announces Fast Track Designation From The United States FDA For Intranasal Naloxone Treatment To Reverse Opioid Overdose 2/17/2015
Bexion Pharmaceuticals Receives Orphan Drug Designation For Saposin C, The Active Ingredient In BXQ-350 For Glioblastoma Multiforme From FDA 2/16/2015
Baxter International, Inc. (BAX) Provides Progress Update On Gene Therapy Program, Including Phase 1/2 Clinical Trial Of BAX 335, Investigational Gene Therapy Treatment For Hemophilia B 2/13/2015
Bristol-Myers Squibb Company (BMY)'s Hepatitis C Drug to Lose Special Breakthrough Status From the FDA 2/12/2015
Protalix Biotherapeutics, Inc. (PLX) Presents Additional Positive Phase I/II Interim Clinical Data On PRX-102 For Fabry Disease At The WORLD Symposium 2/12/2015
Viamet Pharmaceuticals Announces Initiation Of REVIVE Phase 2b Study Of VT-1161 In Recurrent Vulvovaginal Candidiasis 2/12/2015
BIOCEO15: BioLineRx Ltd. CEO Touts New Celiac Drug, Fleshes Out Novartis AG (NVS) Partnership Terms 2/11/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Receipt Of Orphan Drug Designation From The U.S. FDA For Ovarian Cancer 2/11/2015
Mast Therapeutics (MSTX) Announces New Data Supporting Vepoloxamer In Embolic Stroke 2/11/2015
Achillion (ACHN), Gilead (GILD)'s Drug Cocktail Cures Hepatitis C in Six Weeks 2/10/2015
Adamas Pharmaceuticals (ADMS) Phase 2/3 Clinical Study Published In Movement Disorders 2/10/2015
Newcomers Like Aerie Pharmaceuticals, Inc. (AERI), Inotek Pharmaceuticals Corporation Aim to Shake Up Big Pharma With New Wave of Glaucoma Drugs 2/10/2015
Amarantus BioSciences, Inc. Announces Publication In BRAIN Of Eltoprazine Phase 2a Clinical Study For Treating Parkinson's Disease Levodopa-Induced Dyskinesia 2/10/2015
MediciNova, Inc. Announces FDA Approval Of Protocol For Phase 2 Trial Of MN-001 In IPF 2/10/2015
FORUM Pharmaceuticals Initiates Phase 2a Clinical Trial Of FRM-0334 In Frontotemporal Dementia With GRN Mutation 2/10/2015
Aurinia (ISA.TO) To Initiate An Open Label Clinical Study To Investigate The Impact Of Voclosporin On Lupus Nephritis Biomarkers 2/9/2015
Regulus Therapeutics, Inc. (RGLS) Release: All HCV Patients Treated with a Single SC Administration Of 4 Mg/Kg Of RG-101 Responded With Mean Viral Load Reduction Of 4.8 Log10 At Day 29 And 9/14 Patients Are Below The Limit Of Quantification At Day 57 2/9/2015
Achillion (ACHN) Achieves 100% SVR12 In Phase 2 Trial Evaluating 6-Week Combination Treatment With ACH-3102 2/9/2015
Advanced Inhalation Therapies Receives Orphan Drug Designation Of Its Proprietary High Dose Formulation Of Nitric Oxide For Adjunctive Treatment Of Cystic Fibrosis 2/9/2015
Bio-Path Holdings, Inc. (BPTH) Starts Phase II Study With Liposomal Grb-2 In AML Patients 2/9/2015
Kadmon Corporation Announces Publication Highlighting Importance Of ROCK2 In Autoimmunity 2/9/2015
Dermira Announces Positive Phase 2b Results For DRM04 In Patients With Hyperhidrosis 2/6/2015
FDA Snatches Back Breakthrough Status for Merck & Co. (MRK) Hepatitis C Drugs 2/5/2015
Albireo Announces Initiation Of A Phase 2 Trial For A4250, The Company's Lead Compound For Cholestatic Liver Diseases And NASH 2/5/2015
Helsinn Healthcare SA And Zealand Pharma  (ZEAL.CO) Announce The Advance Of Elsiglutide Into Phase 2B Development For The Prevention Of Chemotherapy-Induced Diarrhea 2/5/2015
Zealand Pharma  (ZEAL.CO) And Helsinn Healthcare SA Announce The Advance Of Elsiglutide Into Phase IIB Development For The Prevention Of Chemotherapy-Induced Diarrhea 2/5/2015
Adocia Reports Positive Results From Phase 2a Clinical Study Of Fast-Acting Insulin, HinsBet 2/5/2015
Stock Falls as Columnist Accuses Isis Pharmaceuticals, Inc. (ISIS) of Time-Shifting Diabetes Drug Trial to Embellish Data 2/4/2015
Mast Therapeutics (MSTX) Announces Initiation Of Phase 2a Studies Of AIR001 In Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) 2/4/2015
Can-Fite BioPharma (CFBI) Completes Phase 2/3 Trial For CF101 In Treatment of Psoriasis 2/4/2015
OncoMed Pharmaceuticals, Inc. (OMED) Initiates Dosing In Phase 2 Clinical Trial Of Demcizumab For The Treatment Of Non-Small Cell Lung Cancer 2/4/2015
Qu Biologics Enrolls First Two Participants In Phase 2a Clinical Trial For Lung Cancer 2/4/2015
Ironwood Pharmaceuticals (IRWD) Reports Positive Top-Line Data From Exploratory Phase IIa Trial Of IW-3718 In Refractory Gastroesophageal Reflux Disease 2/4/2015
Isis Pharmaceuticals, Inc. (ISIS)'s Diabetes Drug Effective in Phase 2 Study 2/3/2015
CytoDyn Concludes Phase 2b Study With 98% Success With 4 Weeks Of Monotherapy - Many HIV Patients In Extension Study With Some Approaching 6 Months 2/3/2015
AB Science (AB.PA): Positive Phase 2 Clinical Study Data Of Masitinib In Second-Line Metastatic Stomach Cancer 2/3/2015
BrainStorm Cell Therapeutics Inc. Announces Positive DSMB Recommendation In Ongoing Phase 2 Trial With NurOwn™ In ALS 2/3/2015
Marinus Pharmaceuticals (MRNS) Initiates Clinical Trial With Ganaxolone In PCDH19 Female Pediatric Epilepsy 2/3/2015
Auspex Pharmaceuticals (ASPX) Completes Enrollment In A Pivotal Clinical Trial Of SD-809 In Tardive Dyskinesia 2/3/2015
Immuron Release: Patient Recruitment Commenced For Phase 2 NASH Trial 2/3/2015
Genmab A/S (GEN.CO) Announces Preliminary Results In Phase 2 Study Of Daratumumab In Double Refractory Multiple Myeloma 2/3/2015
Celtaxsys, Inc. Lead Candidate Granted Orphan Designation In Cystic Fibrosis By FDA 2/3/2015
Trevena, Inc. (TRVN) Release: TRV027 Phase 2b BLAST-AHF Trial Design Published In Journal Of The American College Of Cardiology: Heart Failure 2/3/2015
Pierre Fabre Pharmaceuticals Announce Initiation Of Phase 2a Clinical Trial Program For F17464 In Schizophrenia 2/3/2015
Treatment Of The First HIV Positive Patient In ABIVAX's Phase 2a Clinical Trial With ABX464 2/2/2015
Aquinox Pharmaceuticals (AQXP) Completes Enrollment In The Phase 2 FLAGSHIP Trial Of AQX-1125 In Chronic Obstructive Pulmonary Disease Exacerbations 2/2/2015
Lion Biotechnologies, Inc. Announces Allowance Of IND Application To Begin New Phase 2 Study In Metastatic Melanoma 2/2/2015
Ardelyx Inc. (ARDX) Reports Results from Phase 2b Clinical Trial Evaluating Tenapanor In Treating Hyperphosphatemia In Chronic Kidney Disease Patients On Hemodialysis 2/2/2015
Dicerna Pharmaceuticals (DRNA) Announces First Patient Dosed In Phase 1b/2 Clinical Trial Of DCR-MYC, An Investigational Rnai Therapeutic Targeting The MYC Oncogene, In Patients With Advanced Hepatocellular Carcinoma 2/2/2015
Opko Health, Inc. (OPK) Submits Investigational New Drug Application To Initiate A Phase 2a Trial For Its Long-Acting Coagulation Factor Viia-CTP To Treat Hemophilia 2/2/2015
Leading BioSciences Recieves FDA IND Clearance To Proceed With A Randomized, Multi-Center Phase 2 Clinical Trial Using Lb1148 To Treat Septic Shock 2/2/2015
Stemline Therapeutics, Inc. (STML) Announces SL-701 Granted Orphan Drug Designation For The Treatment Of Glioma 1/30/2015
Nuvo Research Inc. (NRI.TO) Reports Topline Results Of Phase 2 Study Of WF10™ For The Treatment Of Allergic Rhinitis 1/30/2015
BioTie Therapies Corp. Announces Top-Line Results From Nepicastat (SYN117) Study In Cocaine Dependence 1/30/2015
Xencor Reports Top-line XmAb®5871 Phase 1b/2a Results Showing Promising Clinical Activity In Rheumatoid Arthritis 1/29/2015
Vericel Completes Patient Enrollment In Phase 2b ixCELL-DCM Clinical Study Of Ixmyelocel-T 1/29/2015
FDA Grants Orphan Drug Designations To OncoMed Pharmaceuticals, Inc. (OMED)'s Tarextumab For The Treatment Of Pancreatic And Small Cell Lung Cancer 1/29/2015
Provectus Biopharmaceuticals Inc. Begins Recruitment For Phase 2 Mechanism Of Action Clinical Trial Of PH-10 For Psoriasis 1/29/2015
Gynecologic Oncology Group Phase 2 Study Of Advaxis, Inc.'s Lm-LLO Immunotherapy, ADXS-HPV, For The Treatment Of Persistent Or Recurrent Cervical Cancer Achieves Safety And Efficacy Criteria 1/28/2015
Sorrento Therapeutics, Inc. Announces Completion Of Enrollment In The Cynviloq™ Registrational TRIBECA™ Study 1/28/2015
Biomay AG Reports Positive Phase 2b Data With The Innovative 3rd Generation Grass Pollen Allergy Vaccine BM32 1/28/2015
Aclaris Therapeutics Announces Positive Results From Phase 2b Clinical Trial Of A-101 For The Removal Of Seborrheic Keratosis, A Common Type Of Benign Skin Tumor 1/27/2015
Naurex Inc.'s First Orally Active Molecule, NRX-1074, Demonstrates Statistically Significant Improvement In Depression Scores Within 24 Hours In Phase 2 Study For Major Depressive Disorder 1/27/2015
Envisia Therapeutics Initiates Phase 2a Clinical Trial For ENV515 In Patients With Glaucoma 1/27/2015
Pivotal Therapeutics Inc. Receives Final Approval For Phase 2a Clinical Trial With PVT-100 1/27/2015
Enlivex Therapeutics Ltd. Granted EU Orphan Drug Designation For Lead Product Apocell For Graft-Versus-Host Disease 1/26/2015
Shire (SHPGY)'s Investigational SHP609, idursulfase-IT, Receives FDA Fast Track Designation For The Treatment Of Neurocognitive Decline Associated With Hunter Syndrome 1/26/2015
Biocryst Pharmaceuticals (BCRX) Release: FDA Grants Fast Track Designation For BCX4161 For The Treatment Of Hereditary Angioedema 1/26/2015
Synageva BioPharma (GEVA) Announces Dosing Of Patients Commenced With SBC-103 In Phase 1/2 Study For Mucopolysaccharidosis IIIB And FDA Fast Track Designation Granted 1/26/2015
Opsona Therapeutics Ltd. Initiates A Prospective Open Label Phase 1/2 Study In Second-Line Lower (Low And Intermediate-1) Risk Myelodysplastic Syndrome (MDS) With OPN-305, A First-In Class Monoclonal Antibody That Blocks Toll-Like Receptor 2 1/26/2015
Genticel To Continue Per Protocol Its Phase 2 Clinical Study With Procervix After 2nd Review By The DSMB 1/26/2015
GlaxoSmithKline (GSK)'s Long-Awaited Ebola Vaccine Due to Arrive in Liberia 1/26/2015
Progenics Pharmaceuticals, Inc. (PGNX) Relaunches Pivotal Trial Of AZEDRA™ In Pheochromocytoma 1/23/2015
Gem Pharmaceuticals Announces Enrollment Of Initial Patients In Its Phase 2 Clinical Trial To Assess The Efficacy And Safety Of GPX-150 In Sarcoma Patients 1/23/2015
CytRx Corporation (CYTR) Announces Overall Survival Results From Its Global Phase 2b Clinical Trial Of Aldoxorubicin In Soft Tissue Sarcoma 1/22/2015
Alexza Pharmaceuticals, Inc. (ALXA) Initiates Phase 2a Study Of AZ-002 (Staccato® alprazolam) In Epilepsy Patients 1/22/2015
Medivation, Inc. (MDVN) Release: Enzalutamide Phase 2 Terrain Trial Demonstrated Statistically Significant Increase In PFS As Compared To Bicalutamide In Metastatic Prostate Cancer 1/22/2015
Ocular Therapeutix, Inc. (OCUL) Enrolls First Patient In Phase 2 Clinical Trial For Sustained Release Dexamethasone For The Treatment Of Dry Eye Disease 1/21/2015
PharmaEngine, Inc. Announces Phase 2 PEPCOL Study Presented At The 2015 American Society of Clinical Oncology GI Of PEP02 (MM-398) In Combination With 5-FU/LV In Unresectable Metastatic Colorectal Cancer 1/21/2015
BioMarin (BMRN), Sarepta (SRPT) Rivalry Gets Nasty in Battle Over Data 1/21/2015
Spark Therapeutics Initiates Phase 1/2 Clinical Trial Of SPK-CHM For Choroideremia, Expanding Its Pipeline Of Potential Treatments For Rare, Blinding Conditions 1/20/2015
TauRx Therapeutics Release: First Evidence Of Potential Efficacy Of Tau Aggregation Inhibitor Therapy In Alzheimer's Disease 1/20/2015
Aduro Biotech Reports Long-Term Survival And Immune Biomarker Data From Phase 2 Clinical Trial Of Its Immuno-Oncology Regimen In Patients With Pancreatic Cancer 1/20/2015
AM-Pharma Starts Adaptive Phase 2 Trial Of Recap In Acute Kidney Injury 1/20/2015
BioInvent (BOVNF)’s Bi-1206 Antibody To Enter Collaborative Phase 1/2 Trial Funded And Conducted By Cancer Research UK, CRT And LLR 1/20/2015
Invion Limited Shows Off Positive Phase 2 Data for Smokers Trying to Quit 1/19/2015
Neurocrine Biosciences, Inc. (NBIX) Announces Granting Of Orphan Drug Status For NBI-77860 In Congenital Adrenal Hyperplasia 1/19/2015
Bone Therapeutics Demonstrates Efficacy In First Patient Cohort In ALLOB® Phase I/IIA Delayed-Union Trial 1/19/2015
J.P. Morgan: Juno Therapeutics (JUNO) Touts 10 New Drugs for Six Diseases, Loves New CAR-T Platform 1/16/2015
Amgen (AMGN) Presents New Data Supporting First-Line Use Of Vectibix® (Panitumumab) In Combination With FOLFOX In Patients With Wild-Type RAS Metastatic Colorectal Cancer 1/16/2015
Immodulon Therapeutics Ltd Release: In IMAGE 1, A Randomised Controlled Phase 2 Clinical Trial, Administration Of IMM-101 With Gemcitabine Demonstrates Significant Survival Advantage Over Gemcitabine Alone 1/16/2015
GenSpera Announces Positive Phase 2 Data For Investigational Agent Mipsagargin 1/16/2015
Phase II Clinical Data Of Peregrine Pharmaceuticals, Inc. (PPHM)' Bavituximab In Combination With Sorafenib Presented At American Society of Clinical Oncology Gastrointestinal Cancers Symposium 1/16/2015
Newron Pharmaceuticals (NWRN) Initiates Phase 2 Study Of sNN0029 In Patients With Amyotrophic Lateral Sclerosis 1/16/2015
Mesoblast Limited (MSB.AX) Reports Positive 24 Month Results In Phase 2 Trial For Chronic Low Back Pain And Initiation Of Phase 3 Program At J.P. Morgan Healthcare Conference 1/15/2015
Amarantus BioSciences, Inc. Announces Positive Data From 140 Subject LP-002 Clinical Study Of Lympro Test® Confirming Statistically Significant Markers For Alzheimer's 1/15/2015
TONIX Pharmaceuticals, Inc. (TNXP) Commences Phase 2 Trial Of TNX-102 SL In Post-Traumatic Stress Disorder 1/15/2015
PharmaCyte Biotech's Pancreatic Cancer Treatment Named As Near-Term Approach To Rising Pancreatic Cancer Rates 1/15/2015
Biocryst Pharmaceuticals (BCRX) Receives Positive Opinion On European Orphan Drug Designation For BCX4161 For The Treatment Of Hereditary Angioedema 1/14/2015
Auris Medical AG (EARS) Achieves 50% Enrollment Milestone In Post-Acute Tinnitus Stratum Of TACTT3 Clinical Trial 1/14/2015
Bellerophon Therapeutics Completes Enrollment In PRESERVATION I, A Trial Of Bioabsorbable Cardiac Matrix (BCM) For The Prevention Of Congestive Heart Failure After A Heart Attack 1/14/2015
Newron Pharmaceuticals (NWRN) Initiates Phase 2 Study Of sNN0031 In Patients With Parkinson’s disease 1/14/2015
Celsus Therapeutics (CLTX) Completes Enrollment Of Phase 2 Trial Of MRX-6 Cream 2% In Pediatric Atopic Dermatitis 1/13/2015
Capricor Therapeutics, Inc. Initiates The DYNAMIC Clinical Trial For The Treatment Of Advanced Heart Failure 1/13/2015
Aduro Biotech Announces Phase 2 Clinical Trial Results For Pancreatic Cancer Combination Immunotherapy Published In Journal Of Clinical Oncology 1/13/2015
Relmada Therapeutics Reaches Midway Point In Dose Escalation For Phase One Study Of Novel NMDA Receptor Antagonist D-Methadone 1/13/2015
Precision Biologics Release: NPC-1C Therapy Provides Hope For Patients With Metastatic Colorectal Cancer Showing Exciting Preliminary Results 1/13/2015
Global Blood Therapeutics Announces First Cohort Dosed In Phase 1/2 Trial Of GBT440 In Sickle Cell Disease 1/13/2015
SAGE Therapeutics Initiates Phase 2a Trial Of SAGE-547 In Postpartum Depression 1/12/2015
Lion Biotechnologies, Inc. CSO Laszlo Radvanyi Co-Authors Study In Clinical Cancer Research 1/12/2015
Celator Pharmaceuticals, Inc. Announces Publication Of Promising Phase 2 Data For CPX-351 In First Relapse Acute Myeloid Leukemia Patients 1/12/2015
Clementia Opens Clinical Trial Site In Europe For Phase 2 Study Of Palovarotene In Patients With Fibrodysplasia Ossificans Progressiva (FOP) 1/12/2015
Arena Pharmaceuticals, Inc. (ARNA) Initiates Phase 2 Clinical Trial Evaluating Ralinepag For Pulmonary Arterial Hypertension 1/12/2015
DelMar Pharmaceuticals Provides Update On VAL-083 Clinical Trial And Outlines Corporate Objectives For 2015 1/12/2015
Milestone Pharmaceuticals Receives FDA Clearance Of MSP-2017 Phase 2 IND 1/12/2015
TapImmune Inc. (TPIV) Release: Positive Phase 1 Immune Responses In All Evaluable Ovarian And Breast Cancer Patients Advances Vaccine To Phase 2 Clinical Trials 1/12/2015
Sorrento Therapeutics, Inc. Provides Status Update On The Cynviloq™ Registrational TRIBECA™ Study 1/12/2015
NovoCure Ltd. Announces The Completion Of Enrollment Of Its PANOVA Trial Of Tumor Treating Fields Plus Gemcitabine For Treatment Of Pancreatic Cancer 1/12/2015
FDA Approves Antria Phase 2 Stem Cell Clinical Trials 1/12/2015
Sarepta Therapeutics (SRPT) Reports Long-Term Outcomes Through 168 Weeks From Phase 2b Study Of Eteplirsen In Duchenne Muscular Dystrophy 1/12/2015
Arrowhead Research Corporation (ARWR) Provides Update On IND For ARC-520 Phase 2b Study 1/12/2015
Anavex Life Sciences Corp. (AVXL) Doses First Alzheimer's Patient In Phase 2a Trial Of ANAVEX 2-73 And ANAVEX PLUS 1/12/2015



//-->